Overview
This episode of Living on the Spectrum covers a Transmitter-reported Nature study on microexon splicing and autism-associated genetic variants; ADDitude reporting on ADHD in older adults, including diagnosis, treatment, menopause, dementia risk, and access; SPARK’s 10-year retrospective; a SPARK family story about level 3 autism and services; and Autism BrainNet’s brain donation program. The conversation emphasizes research limits: many findings are preliminary, observational, or based on subsets, and the speakers distinguish association from causation and diagnosis from individual experience.
Editorial note: The provided article list does not include a title matching the episode’s opening Transmitter segment on microexon splicing. The listed Transmitter article about the BRAIN Initiative and basal ganglia was not discussed and is not summarized here.
Genetics: microexon splicing and autism-associated variants
The Transmitter segment discussed a November 2026 Nature study by Benjamin Blencowe’s team at the University of Toronto. The team built a machine-learning model to predict how genetic variants affect microexon splicing and applied it to genetic data from 7,391 families across three large autism studies.
Microexons are very short sequences, usually 3 to 27 nucleotides long. Splicing is the editing step where those bits get included in or left out of an RNA transcript, which can change how proteins interact and function, especially in the brain. The study also identified 1,514 previously unknown human microexons. The model examines regulatory sequences around microexons—DNA that does not spell out protein but contains instructions—and helps interpret genetic variation there. Lilia Iakoucheva, who was not involved, called the major advance moving from observations of altered splicing toward identifying variants that may contribute.
The study found 72 rare variants predicted to disrupt microexon splicing, present in 2.5 percent of autistic participants but not their non-autistic siblings. About 80 percent of carriers had no prior genetic explanation. Three predicted variants were tested one at a time in human neurons; each altered microexon splicing, reducing inclusion. Hyejung Won said identifying these variants is only the first step, and how individual variants change neuronal function remains unresolved. Iakoucheva also noted it is unclear whether microexons are especially susceptible to autism-associated changes or affected like longer exons.
The conversation stressed that this is a subset finding, not “the autism gene.” In this dataset, 2.5 percent of autistic participants had these predicted variants and their non-autistic siblings did not. That does not mean every autistic person has them, or that carrying one settles a diagnosis. Many variants occurred in genes involved in communication between neurons, including several already linked to autism, but circuit and behavior effects are unresolved. Christopher Park said the work hammers in the importance of splicing and how complex it is.
Inside the Aging ADHD Brain
The ADDitude reporting on older adults emphasized that ADHD does not necessarily get worse with age. The experience can worsen because aging, medical illness, and changing demands pile on top of ADHD. Normal cognitive aging affects memory, time management, organization, and task shifting—areas already affected by ADHD.
There is no “adult-onset” ADHD; a late diagnosis is not a late onset. Rostain drew the distinction between someone who never had ADHD symptoms and is now more forgetful versus someone who has always been distracted. Nadeau said older adults’ memory, routine, and executive-function problems often get interpreted as mild cognitive impairment or dementia.
Zophia heard ADHD discussed on a TV talk show in 2006 when she was 63, after more than 40 years of psychoanalysis, behavioral therapy, and frustration. She was diagnosed and later said, “Why didn’t you come up with that answer a long time ago?” John Washbush was diagnosed at 70 and took his first Ritalin at 72. He said, “For 70 years, I lived my life day-by-day in the dark, totally clueless.”
The episode framed these not as failure stories but as stories about people who compensated for decades without the right frame. The article does not present diagnosis as a cure-all, but describes treatment and understanding as potentially life-changing. Zophia, now 72, said her desire to make a difference was reawakened.
Does ADHD Get Worse with Age? Persistent Symptoms and Smart Treatment in Older Adults
Stimulants remain the treatment of choice for older adults in the article. But there are no control trials of ADHD medications for people over 65, and a stimulant prescription for someone over 65 is technically off label—outside the age range it was formally approved for. Non-stimulants also have no research over 65.
A 2022 meta-analysis of 19 observational studies with 3.9 million participants found no statistically significant association between ADHD medications and cardiovascular disease, even among middle-aged and older adults. It is observational, not randomized, so monitoring still matters, especially with heart conditions and blood pressure.
Estradiol makes neural receptors more sensitive, which helps norepinephrine and dopamine support alertness, focus, and motivation. Quinn says when estrogen drops, dopamine and norepinephrine drop, and cognitive function drops. That happens in all women, but for ADHD women, lower estrogen means symptoms get worse. Many women are diagnosed in their late 30s or 40s during perimenopause. Quinn discusses estrogen therapy, but the article includes cautions; those are individual medical decisions. For men, testosterone gradually decreases and can affect mood, sleep, and cognition.
A 2023 study followed more than 109,000 participants for 17 years. Compared with people without ADHD, those with ADHD had 2.77 times greater dementia risk after adjusting for factors like obesity and diabetes. Medication-treated participants had less risk than unexposed participants. But this is an association, and more research is needed.
Arnold, 73, asks whether a full ADHD diagnosis is worth it when he is functioning okay. The article says it depends on life circumstances, but diagnosis is necessary for medical treatment and for insurance coverage of testing, medication, psychotherapy, and behavioral interventions.
ADHD in Older Adults: Distinct Diagnostic & Treatment Considerations
There is no blood test or brain scan; the gold standard is a careful intake. The DSM-5 requires six impairing symptoms for children 17 and younger but five for adults over 17, and some researchers suggest fewer for people 40 and older.
One article cites about 2 to 3 percent prevalence after age 50. Most clinicians have no training in older-adult ADHD, and Dodson argued that most criteria and questionnaires are child-based, so the mismatch is real.
The episode noted clinicians may lack training in older-adult ADHD, so a second opinion from someone experienced can be reasonable. Telehealth can extend access, though state rules may restrict prescribing across state lines. The point is not that everyone needs a diagnosis; age alone should not be the reason someone is dismissed.
Ten Takeaways From 10 Years of Studying Autism
SPARK launched in 2016. By 2026, the article calls it the largest autism study ever, with 425,000 participants, including 141,500 autistic children and 37,700 autistic adults plus family members. Scientists using SPARK data have published more than 250 papers, and the study helped identify more than 200 autism-related genes and chromosomes. More than 4,000 participants have been notified of a contributing DNA variation; being told is a choice.
Adult research stands out. SPARK made it easier to recruit adults, and more than 60 studies about adults have been published. SPARK also registered 55,500 autistic girls and women, helping researchers study sex differences. Studies found autistic women reported more physical and mental health problems than autistic men; girls were more likely than boys to hide traits as teenagers; and women diagnosed in adulthood reported more anxiety, depression, eating disorders, and substance use disorders than women diagnosed as children. Those are associations, not causal claims.
Gaps remain. The article says autism affects all races and ethnicities equally, but children of color have traditionally been diagnosed later and received fewer autism services than average, and many groups remain underrepresented. Fewer studies focus on youth and adults who do not speak or have intellectual disability than on autistic people who speak or have average-range IQ; SPARK data is being used to identify depression in autistic adults with little or no speech.
Jacob Michaelson said change-over-time data is “just like gold,” because researchers want to understand how and why things get better, not only worse.
A Mother's Mission to Find Services for Her Sons with Level 3 Autism
SPARK’s October 2026 family story profiles Laura Youker and her children, Marley, 7, and Carter, 5. Both have level 3 autism, which means they need the highest level of daily support. They do not speak and have learning disabilities and developmental delays. The article says level 3 autism affects an estimated one-fourth of autistic people.
Almost half of children with autism wander or run away from safe places—elopement. A National Autism Association report cited by SPARK says about 17 percent of elopement cases resulted in an autistic person’s death. Laura uses locks, chains, an adaptive stroller, and GPS. Carter once got out, removed the clothing holding his tracker, and was found by a police helicopter an hour later, uninjured and headed toward a park. His mother recorded 37,000 steps on him in one day.
The article is not only about risk. Marley and Carter are affectionate. Marley loves cake pops, Carter loves Spider-Man, and both love hugs, fireworks, and many foods. They use an AAC tablet, where nonspeaking people select pictures and words. They like tapping “big” and “doughnut,” and they lead their mother to what they want and have learned to point. Laura hopes for better speech therapies, but says if they do not talk, that is okay as long as they can communicate. She sees “glimmers of how smart they are.”
The article also makes a sensory point. Marley and Carter seek sensory input, which is different from the more familiar sensitivity profile. The episode stressed not to generalize their experience to all autistic people. Many autistic people find lights too bright, sounds too loud, or textures uncomfortable. Marley and Carter enjoy being hugged, running and moving, food smells, fireworks, people, and noise. Laura created a service map and shares it, serves on SPARK’s Community Advisory Council, and Marley joined a university study of autistic children with large heads; the article does not report its results.
Autism BrainNet: Advancing Research Through the Gift of Brain Donation
Autism BrainNet, a Simons Foundation Autism Research Initiative program, works on brain tissue donation after death. Temple Grandin is a future donor. The page announces new omics data—large-scale molecular data—but gives no details; it is more landing page than study report.
The episode noted the page does not provide methods or results for that data release and should be treated as a pointer, not a finding.
Podcast Transcript
Aaron: Welcome to Living on the Spectrum, where we connect research and community conversation about autism, ADHD, sensory processing, language, and other neurodevelopmental differences. I’m Aaron, and with me is Jamie. We’re starting with a genetics story that sounds technical but has a very human question underneath: how do small changes in DNA shape brain development?
Jamie: The Transmitter covered a Nature study in November 2026 by Benjamin Blencowe’s team at the University of Toronto. They built a machine-learning model to predict how genetic variants affect microexon splicing and applied it to genetic data from 7,391 families across three large autism studies. They found 72 rare variants predicted to disrupt microexon splicing, present in 2.5 percent of autistic participants but not their non-autistic siblings. About 80 percent of carriers had no prior genetic explanation.
Aaron: Slow us down. What is a microexon, and what is splicing?
Jamie: Microexons are very short sequences, usually 3 to 27 nucleotides long. Splicing is the editing step where those bits get included in or left out of an RNA transcript. That can change how proteins interact and function, especially in the brain. This study also identified 1,514 previously unknown human microexons.
Aaron: So this is not just about genes that spell out proteins. It is also about the instructions around them.
Jamie: The model examines regulatory sequences around microexons—parts of DNA that don’t spell out protein but contain instructions—and helps interpret genetic variation there. Lilia Iakoucheva, who was not involved, called the major advance moving from observations of altered splicing toward identifying variants that may contribute.
Aaron: Did they test any predictions?
Jamie: Yes, three predicted variants, one at a time in human neurons. Each altered microexon splicing, reducing inclusion. But Hyejung Won said identifying these variants is only the first step; how individual variants change neuronal function remains unresolved. Iakoucheva also noted it is unclear whether microexons are especially susceptible to autism-associated changes or affected like longer exons.
Aaron: So this is not “scientists found the autism gene.” It is a subset finding.
Jamie: Right. In this dataset, 2.5 percent of autistic participants had these predicted variants and their non-autistic siblings did not. That does not mean every autistic person has them, or that carrying one settles a diagnosis. Many of the variants occurred in genes involved in communication between neurons, including several already linked to autism, but circuit and behavior effects are unresolved. Christopher Park said the work hammers in the importance of splicing, and how complex it is.
Aaron: The everyday takeaway I hear is that genetics is not one switch. It can be many small regulatory changes, some in regions we used to skip over. That connects to the next topic: the gap between what research measures and what people live with. Aging with ADHD is a good example.
Jamie: The ADDitude reporting on older adults is useful here. One headline is that ADHD does not necessarily get worse with age. The experience can worsen because aging, medical illness, and changing demands pile on top of ADHD. Normal cognitive aging affects memory, time management, organization, and task shifting—areas already affected by ADHD. And there is no “adult-onset” ADHD. A late diagnosis is not a late onset.
Aaron: How do clinicians tell it apart from mild cognitive impairment or dementia?
Jamie: Rostain drew the distinction between someone who never had ADHD symptoms and is now more forgetful versus someone who has always been distracted. Nadeau said older adults’ memory, routine, and executive-function problems often get interpreted as mild cognitive impairment or dementia. There is no blood test or brain scan; the gold standard is a careful intake. The DSM-5 requires six impairing symptoms for children 17 and younger but five for adults over 17, and some researchers suggest fewer for people 40 and older.
Aaron: How common is ADHD in this age group?
Jamie: One article cites about 2 to 3 percent prevalence after age 50. Most clinicians have no training in older-adult ADHD, and Dodson argued that most criteria and questionnaires are child-based, so the mismatch is real.
Aaron: The personal stories are striking. Zophia heard ADHD discussed on a TV talk show in 2006 when she was 63, after more than 40 years of psychoanalysis, behavioral therapy, and frustration. She was diagnosed and later said, “Why didn’t you come up with that answer a long time ago?” John Washbush was diagnosed at 70 and took his first Ritalin at 72. He said, “For 70 years, I lived my life day-by-day in the dark, totally clueless.”
Jamie: Those are not failure stories. They are stories about people who compensated for decades without the right frame. The article does not present diagnosis as a cure-all, but describes treatment and understanding as potentially life-changing. Zophia, now 72, said her desire to make a difference was reawakened.
Aaron: What about treatment evidence? I want the careful version.
Jamie: Stimulants remain the treatment of choice for older adults in the article. But there are no control trials of ADHD medications for people over 65, and a stimulant prescription for someone over 65 is technically off label—meaning outside the age range it was formally approved for. Non-stimulants also have no research over 65. A 2022 meta-analysis of 19 observational studies with 3.9 million participants found no statistically significant association between ADHD medications and cardiovascular disease, even among middle-aged and older adults. It is observational, not randomized, so monitoring still matters, especially with heart conditions and blood pressure.
Aaron: What about estrogen and perimenopause?
Jamie: Estradiol makes neural receptors more sensitive, which helps norepinephrine and dopamine support alertness, focus, and motivation. Quinn says when estrogen drops, dopamine and norepinephrine drop, and cognitive function drops. That happens in all women, but for ADHD women, lower estrogen means symptoms get worse. Many women are diagnosed in their late 30s or 40s during perimenopause. Quinn discusses estrogen therapy, but the article includes cautions; those are individual medical decisions. For men, testosterone gradually decreases and can affect mood, sleep, and cognition.
Aaron: There was also a dementia study.
Jamie: A 2023 study followed more than 109,000 participants for 17 years. Compared with people without ADHD, those with ADHD had 2.77 times greater dementia risk after adjusting for factors like obesity and diabetes. Medication-treated participants had less risk than unexposed participants. But this is an association, and more research is needed.
Aaron: Arnold, 73, asks whether a full ADHD diagnosis is worth it when he is functioning okay. The article says it depends on life circumstances, but diagnosis is necessary for medical treatment and for insurance coverage of testing, medication, psychotherapy, and behavioral interventions.
Jamie: The article notes clinicians may lack training in older-adult ADHD, so a second opinion from someone experienced can be reasonable. Telehealth can extend access, though state rules may restrict prescribing across state lines. The point isn’t that everyone needs a diagnosis; age alone shouldn’t be the reason someone is dismissed.
Aaron: Let’s shift to the SPARK ten-year retrospective. This is a big-picture research story. What should listeners know?
Jamie: SPARK launched in 2016. By 2026, the article calls it the largest autism study ever, with 425,000 participants, including 141,500 autistic children and 37,700 autistic adults plus family members. Scientists using SPARK data have published more than 250 papers, and the study helped identify more than 200 autism-related genes and chromosomes. More than 4,000 participants have been notified of a contributing DNA variation; being told is a choice.
Aaron: What stands out beyond the scale?
Jamie: Adult research stands out. SPARK made it easier to recruit adults, and more than 60 studies about adults have been published. SPARK also registered 55,500 autistic girls and women, helping researchers study sex differences. Studies found autistic women reported more physical and mental health problems than autistic men; girls were more likely than boys to hide traits as teenagers; and women diagnosed in adulthood reported more anxiety, depression, eating disorders, and substance use disorders than women diagnosed as children. Those are associations, not causal claims.
Aaron: And there are still gaps.
Jamie: The article says autism affects all races and ethnicities equally, but children of color have traditionally been diagnosed later and received fewer autism services than average, and many groups remain underrepresented. Fewer studies focus on youth and adults who do not speak or have intellectual disability than on autistic people who speak or have average-range IQ; SPARK data is being used to identify depression in autistic adults with little or no speech. Jacob Michaelson said change-over-time data is “just like gold,” because researchers want to understand how and why things get better, not only worse.
Aaron: That leads to SPARK’s October 2026 family story about Laura Youker and her children, Marley, 7, and Carter, 5. Both have level 3 autism, which means they need the highest level of daily support. They do not speak and have learning disabilities and developmental delays. The article says level 3 autism affects an estimated one-fourth of autistic people.
Jamie: Almost half of children with autism wander or run away from safe places—elopement. A National Autism Association report cited by SPARK says about 17 percent of elopement cases resulted in an autistic person’s death. Laura uses locks, chains, an adaptive stroller, and GPS. Carter once got out, removed the clothing holding his tracker, and was found by a police helicopter an hour later, uninjured and headed toward a park. His mother recorded 37,000 steps on him in one day.
Aaron: That is a lot for a family to carry. But the article is not only about risk.
Jamie: Marley and Carter are affectionate. Marley loves cake pops, Carter loves Spider-Man, and both love hugs, fireworks, and many foods. They use an AAC tablet, where nonspeaking people select pictures and words. They like tapping “big” and “doughnut,” and they lead their mother to what they want and have learned to point. Laura hopes for better speech therapies, but says if they do not talk, that is okay as long as they can communicate. She sees “glimmers of how smart they are.”
Aaron: The article also makes a sensory point. Marley and Carter seek sensory input, which is different from the more familiar sensitivity profile.
Jamie: The article contrasts this with the more familiar sensitivity profile, and it’s important not to generalize their experience to all autistic people. Many autistic people find lights too bright, sounds too loud, or textures uncomfortable. Marley and Carter enjoy being hugged, running and moving, food smells, fireworks, people, and noise. Laura created a service map and shares it, serves on SPARK’s Community Advisory Council, and Marley joined a university study of autistic children with large heads; the article does not report its results.
Aaron: Before we close, one smaller item. Autism BrainNet, a Simons Foundation Autism Research Initiative program, works on brain tissue donation after death. Temple Grandin is a future donor. The page announces new omics data—large-scale molecular data—but gives no details; it is more landing page than study report.
Jamie: It is another research pathway, but the page does not provide methods or results for that data release. I would treat it as a pointer, not a finding.
Aaron: That wraps today’s episode. Thanks for listening to Living on the Spectrum. We’ll have links to the studies and stories we mentioned on the episode page, so you can go deeper. Take care.
Jamie: Thanks, everyone.
References
- New phase of BRAIN Initiative spawns basal ganglia ‘parts list’
- Inside the Aging ADHD Brain
- Does ADHD Get Worse with Age? Persistent Symptoms and Smart Treatment in Older Adults
- ADHD in Older Adults: Distinct Diagnostic & Treatment Considerations
- Ten Takeaways From 10 Years of Studying Autism
- A Mother's Mission to Find Services for Her Sons with Level 3 Autism
- Autism BrainNet: Advancing Research Through the Gift of Brain Donation
